Scinai Immunotherapeutics Secures $10M Equity Line

TL;DR

Scinai just inked a $10M equity deal for future funding flexibility.

AI Summary

On March 5, 2025, Scinai Immunotherapeutics Ltd. announced a $10 million Standby Equity Purchase Agreement. This agreement provides the company with a flexible financing option to support its ongoing operations and strategic initiatives.

Why It Matters

This $10 million equity line offers Scinai Immunotherapeutics financial flexibility, potentially enabling them to fund research, development, or operational needs without immediate dilution.

Risk Assessment

Risk Level: medium — Standby equity agreements can indicate potential financial pressure or a need for capital, which may carry inherent risks for investors.

Key Numbers

• $10.0M — Standby Equity Purchase Agreement (Provides potential capital infusion for the company.)

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Registrant
• $10 Million (dollar_amount) — Standby Equity Purchase Agreement amount
• March 5, 2025 (date) — Date of press release and agreement announcement
• BiondVax Pharmaceuticals Ltd. (company) — Former company name

FAQ

From the Filing

0001213900-25-020786.txt : 20250305 0001213900-25-020786.hdr.sgml : 20250305 20250305171033 ACCESSION NUMBER: 0001213900-25-020786 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250305 FILED AS OF DATE: 20250305 DATE AS OF CHANGE: 20250305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 25712330 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0233227-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note On March 5, 2025, Scinai Immunotherapeutics Ltd. issued a press release announcing $10 Million Standby Equity Purchase Agreement. A copy of the press release is furnished herewith as Exhibit 99.1. This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit Index Exhibit No. Description 99.1 Press release dated March 5, 2025 . 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: March 5, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2 EX-99.1 2 ea023322701ex99-1_scinai.htm PRESS RELEASE DATED MARCH 5, 2025 Exhibit 99.1 SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT JERUSALEM, March 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”), a fund managed by Yorkville Advisors Global, LP. Under the terms of the SEPA, Scinai has the right, but not the obligation, to sell up to $10 million (the “Commitment Amount”) of its American Depository Shares (“ADSs”), each representing 4,000 ordinary shares, to Yorkville at any time during the three-year period following the execution date of the SEPA and following the effectiveness of a registration statement filed with the Securities and Exchange Commission registering the ordinary shares represented by the ADSs issuable pursuant to the SEPA. Sales to Yorkville under the SEPA are subject to a beneficial ownership